Galanopoulos Andreas

Galanopoulos Andreas Neurologist

Education & Academic Qualifications

  • PhD in Neurosciences, grade “excellent” (2013)
  • M.Sc. in Neurosciences, grade “excellent” (2004)
  • Title of medical specialty of Neurology (2008)
  • Graduation of the Medical School of National and Kapodistrian University of Athens (1998)


Doctoral thesis

  • The role of the endogenous cannabinoid system in behavioural and neurobiological aspects of cognition. An experimental study in rats.

Fellowship in Societies, Membership in Journal Editorial Committees

  • Member of the European Academy of Neurology

  • Member of the International Parkinson and Movement Disorder Society

  • Member of the Hellenic Neurological Association

  • Member of the Athens Association of Alzheimer’s Disease and Related Disorders


Work Experience

  • Neurologist at the HYGEIA Hospital since 2012

  • Private neurological office in Pallini, Attiki, since 2008

  • Resident at the Neurology Department of the General Hospital of Piraeus “o Ag. Panteleimon”, 2004-2008

  • Resident at the 2nd Psychiatry Department of Psychiatric Hospital of Chania, Crete, 2002-2003

  • Participation in scientific activities of the Laboratory of Neurosciences and Behaviour, at Psychology Department of University of Crete, 2003-2004

  • Resident at the 2nd Internal Medicine Department of the General Hospital of Athens “Elpis”, 2002

  • Military service in the Hellenic Army as a doctor, 2000-2001

  • Rural medical service at the Hospital of Molai, Lakonia, 1998-2000

Education Experience:

  • Contribution in education of medical, biology, psychology undergraduate and postgraduate students


Clinical & Research Interest

Clinical Interest:

  • Memory deficits – Alzheimer’s Disease and other types of dementia

  • Multiple Sclerosis and other demyelinating disorders

  • Parkinson’s Disease and movement disorders

  • Headache, neuralgia and neuropathic pain

  • Diseases of the Spinal Cord and Peripheral Nerves (neuritis and neuropathies)

Research Interest:

  • Neurosciences-Brain neurotransmission

  • Neurobiological mechanisms involved in memory and learning

  • Cognition and Dementia

  • Parkinson’s Disease and other neurodegenerative disorders


Honors & Awards

  • Granted by “Latsis Foundation” during all years of undergraduate and postgraduate studies

  • More than 15 lectures in Congresses concerning Dementia and Parkinson’s Disease


Recent Publications

  • WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation. Pharmacol Biochem Behav. 2014 Sep;124:58-66,Galanopoulos A, Polissidis A, Georgiadou G, Papadopoulou-Daifoti Z, Nomikos GG, Pitsikas N, Antoniou K

  • The effectiveness of memantine in a “behaviourally disturbed” AD population. Re-sults from a Greek observational, open-label, 6-month study. Journal of the Neuro-logical Sciences 333 (2013):e351, Galanopoulos A, Saltos L, Kerezoudi E, Parashos I

  • Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine. Behav Brain Res. 2014 Aug 15;270:261-9, Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, Antoniou K

  • The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. Int J Neuropsychopharma-col. 2013 Mar;16(2):393-403, Polissidis A, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, An-toniou K

  • Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord. 2011;32(4):267-72, Forstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M

  • Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner. Behav Brain Res. 2011 Oct 10;224(1):65-72, Galanopoulos A, Polissidis A, Papadopoulou-Daifoti Z, Nomikos GG, Antoniou K

  • Extensive hypertensive encephalopathy completely reversed after successful treatment. European Journal of Neurology 17 (2010, Suppl. 3), 72–350, Galanopoulos A, Xifaras M, Polissidis A, Papadopoulou-Daifoti Z

  • Ιndividual differences in the effects of cannabinoids on motor activity, dopaminer-gic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2010 Oct;13(9):1175-91, Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K

  • Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sci. 2009 Jul 31;85(5-6):248-54, Polissidis A, Chouliara O, Galanopoulos A, Marselos M, Papadopoulou-Daifoti Z, An-toniou K

  • Behavioral pharmacological properties of a novel cannabinoid 1′,1′-dithiolane del-ta8-THC analog, AMG-3. Behavioural Pharmacology. 2005 Sep; 16(5-6):499-510. An-toniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C